鼎里的药是历久弥新的价值承诺——专访广誉远李晓军

Core Viewpoint - Guangyuyuan, a "Chinese Time-Honored Brand," is focusing on growth as a fundamental objective, emphasizing the importance of maintaining a competitive edge through strategic product positioning and operational efficiency [7][8][9]. Company Strategy - The company has adopted the "1541" strategic framework to promote growth as a primary goal, launching the "Dragon and Phoenix Big Product" strategy centered around its core products, Gui Ling Ji and Ding Kun Dan [8][9]. - In 2024, Guangyuyuan opened 43 new agents, increasing its total terminal stores to 462, with Gui Ling Ji sales growing over 25% and Ding Kun Dan nearly 10% [8]. Financial Performance - In Q1 2025, Guangyuyuan reported revenue of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% [8]. Market Outlook - The health policy in China is expected to drive the market for premium traditional Chinese medicine, projected to exceed 300 billion yuan by 2030, aligning with Guangyuyuan's dual attributes of "treatment necessity + consumption upgrade" [9]. Product Development - Guangyuyuan emphasizes the importance of product efficacy, adhering to traditional methods in the production of its medicines, which include strict selection standards for raw materials [11][12]. - The company is also engaged in innovative research and development in collaboration with institutions like the China Academy of Chinese Medical Sciences [12]. Marketing and Growth Strategy - Guangyuyuan is implementing a "Four Feet and Two Wings" marketing strategy to enhance its market position and aims to become a leader in the premium traditional Chinese medicine sector within three years [13][14]. - The company is focusing on a multi-dimensional approach to marketing, including partnerships with top media and consulting firms to enhance brand visibility and market penetration [14][15].